Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
Public ClinicalTrials.gov record NCT05418088. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I Clinical Trial of Anti-CD19/20/22 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, B-Prolymphocytic Leukemia)
Study identification
- NCT ID
- NCT05418088
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Sumithira Vasu
- Other
- Enrollment
- 54 participants
Conditions and interventions
Conditions
- Recurrent Acute Lymphoblastic Leukemia
- Recurrent B Acute Lymphoblastic Leukemia
- Recurrent B-Cell Prolymphocytic Leukemia
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent High Grade B-Cell Lymphoma
- Recurrent Indolent Non-Hodgkin Lymphoma
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Transformed Chronic Lymphocytic Leukemia
- Refactory Childhood Acute Lymphoblastic Leukemia
- Refractory Acute Lymphoblastic Leukemia
- Refractory B Acute Lymphoblastic Leukemia
- Refractory B-Cell Prolymphocytic Leukemia
- Refractory Childhood Non-Hodgkin Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Refractory High Grade B-Cell Lymphoma
- Refractory Indolent Non-Hodgkin Lymphoma
- Refractory Non-Hodgkin Lymphoma
- Refractory Transformed Chronic Lymphocytic Leukemia
Interventions
- Anti-CD19/CD20/CD22 CAR T-Cells Biological
- Biopsy Procedure
- Biospecimen Collection Procedure
- Bone Marrow Aspiration and Biopsy Procedure
- Cyclophosphamide Drug
- Echocardiography Procedure
- Fludarabine Phosphate Drug
- Multigated Acquisition Scan Procedure
- Pheresis Procedure
Biological · Procedure · Drug
Eligibility (public fields only)
- Age range
- 2 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 29, 2022
- Primary completion
- Apr 29, 2026
- Completion
- Jul 30, 2026
- Last update posted
- May 15, 2025
2022 – 2026
United States locations
- U.S. sites
- 2
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Nationwide Children's Hospital | Columbus | Ohio | 43203 | Recruiting |
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05418088, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 15, 2025 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05418088 live on ClinicalTrials.gov.